SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as traders anticipate upcoming maintenance trial data for VK2735, with many viewing the results as a critical catalyst to differentiate the drug's efficacy and tolerability from competitors. The community remains divided, with some investors expecting a major revaluation or buyout potential, while others express frustration over the stock's recent price stagnation and management's communication strategy.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

A quarterly update showing a modest earnings beat and a less-negative organic-sales outlook has renewed attention on Kraft Heinzs turnaround under new management. Traders are split between bullish views on the companys valuation, cash flow, dividend and consumer-staples rotation, and concerns about weak sales, margin pressure, impairment charges and potential dividend risk.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

BITO is facing selling pressure as traders speculate on a potential broader market correction, with many expressing frustration over the recent decline in dividend payouts. While some investors are utilizing the lower price points to accumulate shares for a long-term bullish cycle, others are vocal about the risks of NAV decay and market volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is facing downward pressure following the implementation of price increases in its second-largest market, the United Kingdom, leading to debate among traders over whether these hikes will boost revenue or trigger subscriber churn. While some investors view the stock's pullback as a buying opportunity given the company's strong cash flow and content investment, others express frustration with the lack of sustained momentum and the tendency for capital to rotate into semiconductor and AI-related stocks.

McDonald's Corp. engages in the operation and franchising of restaurants. The firm operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. Its products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, and McCafe beverages. The company was founded by Raymond Albert Kroc on April 15, 1955 and is headquartered in Chicago, IL.

McDonald`s Corp

McDonald's Corp

McDonald's shares have been trending amidst a period of price volatility and technical weakness, with market participants debating whether the stock's proximity to 52-week lows represents a generational buying opportunity for a blue-chip dividend play or a signal of deeper structural decline. Community sentiment remains polarized, as some traders highlight the company's real estate value and defensive nature, while others express frustration over declining consumer spending and negative market sentiment toward the fast-food sector.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is trending amid active debate regarding its ability to sustain support levels above $2,500, with traders divided between bullish sentiment driven by institutional adoption and tokenization developments and bearish skepticism regarding macroeconomic pressures and persistent resistance. Community discussion frequently emphasizes Ethereum's correlation with Bitcoin's momentum while traders closely watch funding rates and potential short liquidations.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is drawing significant investor attention due to robust insider buying, specifically a massive purchase by top leadership, following the company's decision to withdraw its previously announced secondary stock offering. The market remains focused on the upcoming regulatory catalyst for its lead oncology candidate, ivonescimab, despite persistent short interest and ongoing debate regarding the company's long-term capital requirements.

The Campbell's Co. engages in the business of manufacturing and marketing food and beverage products. It operates under the Meals and Beverages, and Snacks segments. The Meals and Beverages segment includes soup, meals, and beverage products in retail and foodservice. The Snacks segment offers cookies, crackers, bakery, and frozen products. The company was founded by Joseph Campbell and Abraham Anderson in 1869 and is headquartered in Camden, NJ.

Campbells Co (The)

Campbell Soup Co.

Campbell Soup is facing downward pressure following a weaker-than-expected annual sales and earnings forecast and a significant dividend cut. While some traders view the stock as a long-term value play and a potential turnaround candidate due to debt reduction efforts, others are cautious of the persistent weakness in consumer demand and ongoing snacks segment struggles.

Ambarella, Inc. engages in the development of low-power system-on-a-chip (SoC), semiconductors, and software for edge artificial intelligence (AI) applications and intelligent automation. The firm's products include video security, advanced driver assistance (ADAS), electronic mirror, drive recorder, driver or cabin monitoring, autonomous driving, and other robotics applications. It operates through the following geographical segments: Taiwan, Asia Pacific, Europe, North America, and United States. The company was founded by Feng Ming Wang and Leslie D. Kohn on January 15, 2004 and is headquartered in Santa Clara, CA.

Ambarella Inc

Ambarella shares are trending amid mixed investor sentiment following recent quarterly results, with the conversation dominated by debates over the company's long-term potential in edge AI and robotics versus concerns regarding supply chain costs and revenue concentration. While some traders view the stock as a promising "physical AI" play, others highlight significant volatility and skepticism surrounding its ability to achieve sustained profitability.

Vanguard Index Funds - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

The primary catalyst for VOO trending is heightened market anxiety over geopolitical instability in the Middle East and concerns regarding bond market volatility, which has led traders to debate whether current market valuations are sustainable. Discussion is fragmented between investors advocating for a "VOO and chill" long-term compounding approach and those speculating on an imminent correction due to concerns about the U.S. economy, debt levels, and the perceived overvaluation of AI-driven tech stocks.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14 at 7:45 a.m. ET in New York City, New...

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2026. This is a pivotal time for the CHD community, when availability of new therapies could improve awareness, testing and access to care. At EASL, experts...

Vir Biotechnology Announces Chief Financial Officer Transition

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason OByrne is leaving the Company to pursue another opportunity and will remain with Vir...

Vir Biotechnology to Host Conference Call for Second Quarter 2026 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the...

Vir Biotechnology Announces Appointment of Timothy Coughlin to its Board of Directors

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. We are pleased to welcome Tim to Vir Biotechnologys Board of Directors at a pivotal moment for the company, said Marianne...

Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?

Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now...

Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally

Key PointsSuperstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices...

Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta...

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Vir Biotechnology Inc

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership

Equity

Neutral Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Current Price	$11.39
Prev Close	$11.45
Open	$11.31
Dividend Yield	0.00%
50-Day Moving Average	$9.74
Beta	1.56
Avg. Volume	1.72M
PE Ratio	-6.12

52-Week High	$11.94
52-Week Low	$4.75
Market Capitalization	$1.94B
EPS (Annual)	-$3.16
Price to Book	1.96
Revenue Per Employee	$186,801.09

Feed

News

Sentiment

Earnings

Fundamentals

Info

VIR Fundamentals